TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00243152
Drug: Placebo (for Lamotrigine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugar pill manufactured to mimic Lamotrigine tablets
Study: NCT01149824
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01692366
Drug: SAR302503
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form:Capsule~Route of administration: oral
Study: NCT00668096
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching Placebo
Study: NCT03079388
Drug: Monthly intermittent preventive treatment of malaria during pregnancy (IPTp)
Normalized name: Plasmodium malariae
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulfadoxine-pyrimethamine (500 mg / 25 mg) given every 4 weeks, beginning at enrollment or at 13 weeks' gestation, whichever is later.
Study: NCT03079388
Drug: Standard intermittent preventive treatment of malaria during pregnancy (IPTp)
Normalized name: Plasmodium malariae
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care for Sierra Leone is 2 doses of sulfadoxine/ pyrimethamine (500mg/ 25mg).
Study: NCT03079388
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azithromycin 1 gram given once in second trimester and again during weeks 28-34 of gestation.
Study: NCT03915561
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo group (0.9% saline, group S) will be received intravenous injection with 10ml 0.9% saline alone (transparent solution) twice.
Study: NCT00497679
Drug: AZD1152
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7-day continuous intravenous infusion
Study: NCT01643434
Drug: Spironolactone
Normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Spironolactone (titrating dose from 12.5 to 50mg SID)
Study: NCT02497235
Drug: [18F]MNI-792 (tracer)
Approvals — FDA: no, EMA: no, PMDA: no
Description: \[18F\]MNI-792 injection.
Study: NCT02342041
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01291641
Drug: HMG-CoA Reductase Inhibitor
Normalized name: HMG-CoA reductase inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: During the study period, HMGCoA reductase inhibitor is continuously administered to the patients.~Dosage regimen: following the package insert of each HMGCoA reductase inhibitor
Study: NCT02247518
Drug: Cialis Tab. 5mg
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02247518
Drug: Harnal-D Cap. 0.2mg
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00865124
Drug: Spironolactone
Normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 25 mg capsule daily for 6 months
Study: NCT00865124
Drug: Hydrochlorothiazide + potassium
Normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: hydrochlorothiazide (HCTZ) + potassium, 12.5 mg/10 milliequivalents (mEq) capsule daily
Study: NCT03815331
Drug: Xiaflex®
Approvals — FDA: no, EMA: no, PMDA: no
Description: medication indicated for the treatment of adult men with Peyronie's disease with a palpable plaque and curvature deformity of at least 30 degrees at the start of therapy. Xiaflex belongs to a family of enzymes called collagenases. Collagenases are proteinases that hydrolyze collagen in its native triple helical conformation under physiological conditions, resulting in lysis of collagen deposits. The signs and symptoms of Peyronie's disease are caused by a collagen plaque. Injection of XIAFLEX into a Peyronie's plaque, which is comprised mostly of collagen, may result in enzymatic disruption of the plaque. Following this disruption of the plaque, penile curvature deformity and patient bother caused by Peyronie's disease are reduced
Study: NCT00742534
Drug: Intravenous L-Citrulline
Approvals — FDA: no, EMA: no, PMDA: no
Description: This is a classic dose escalation using initial doses of 10 mg/kg of intravenous citrulline and advancing the dose by 10 mg/kg every 3 patients for a target peak plasma citrulline concentration of 100 umol/L. This regimen will be adjusted with pharmacokinetic data as it becomes available so that it may be adjusted to maintain appropriate serum levels of the urea cycle precursors and NO metabolites of interest.
Study: NCT04810533
Drug: [14C] SH-1028
Approvals — FDA: no, EMA: no, PMDA: no
Description: Volunteer will receive a single oral dose of 200 mg/88 uCi \[14C\]SH-1028 as a solution on Day 1
Study: NCT02377388
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo tablets, 48(+-24) hours after the beginning of an AMI,and both arms in use of dual anti-platelet therapy (DAPT) .
Study: NCT02653729
Drug: Espidone
Normalized name: Equidone
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02653729
Drug: Olepra
Normalized name: DRUGS FOR TREATMENT OF LEPRA
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03393481
Drug: MAA868
Approvals — FDA: no, EMA: no, PMDA: no
Description: MAA868 dose 1 and dose 2, single administration, subcutaneous,
Study: NCT00769314
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg muco-adhesive buccal tablets, single application on the gum
Study: NCT01417273
Drug: Drug: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 cap placebo/day for 12 month
Study: NCT00005970
Drug: Aromatase Inhibition Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given orally
Study: NCT00005970
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00005970
Drug: Doxorubicin Hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT00706719
Drug: 25 mg Androxal
Normalized name: testosterone 20.25 MG/ACTUAT [Androgel]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg Androxal capsules, 1 capsule daily for 6 months
Study: NCT01694589
Drug: LDE-225
Normalized name: LANCET,STERILANCE LDE 2 DEVICE
Approvals — FDA: no, EMA: no, PMDA: no
Description: LDE-225 capsules will be administered as a fixed dose of 800 mg daily for two weeks.
Study: NCT00331279
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo pills in likeness of the cinnamon extract
Study: NCT00041327
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 750 mg/m2 IV on day 5
Study: NCT00041327
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10 mg/m2/day as a continuous 96-hour infusion days 1-4
Study: NCT02998541
Drug: SHP640
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive one drop of SHP640 (0.1 % dexamethasone and 0.6% PVP-I) ophthalmic suspension in each eye QID (with a minimum of 2 hours between doses) for 7 days.
Study: NCT02998541
Drug: PVP-I 0.6%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive one drop of PVP-I ophthalmic solution in each eye QID (with a minimum of 2 hours between doses) for 7 days.
Study: NCT02769325
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV saline, 10 ml
Study: NCT02769325
Drug: Ketorolac
Normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 60 mg IV ketorolac will be administered at induction, and patients will receive 30mg/8h on the postoperative period
Study: NCT02576717
Drug: RPC1063
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00633698
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Week 1-4: 500 mg per day Week 5-8: 1000 mg per day Week 9-12: 1500 mg per day Week 13-20: 2000 mg per day
Study: NCT01040273
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00137046
Drug: Subcutaneous Insulin
Normalized name: subcutaneous insulin pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous insulin with dose adjusted according to premeal blood glucose
Study: NCT00137046
Drug: Inhaled Insulin
Normalized name: insulin, regular, human Inhalation Powder [Afrezza]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled insulin with dose adjusted according to premeal blood glucose
Study: NCT03171324
Drug: Iron Supplement
Normalized name: Iron supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg/kg/day elemental iron
Study: NCT01984606
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching empagliflozin
Study: NCT01984606
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching sitagliptin
Study: NCT03733587
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide 500mg/vial
Study: NCT01913054
Drug: Fentanyl Injection
Normalized name: fentanyl Injection
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01746654
Drug: P128-0.1 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: P-128 at 0.1 mg divided evenly between the nares is administered once in Part A; multiple times in Part B and Part C; and once in Part D.
Study: NCT01746654
Drug: P128-0.3 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: P-128 at 0.3 mg divided evenly between the nares is administered once in Part A; multiple times in Part B and Part C; and once in Part D.
Study: NCT01746654
Drug: P128-1.0 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: P-128 at 1.0 mg divided evenly between the nares is administered once in Part A; multiple times in Part B and Part C; once in Part D.
Study: NCT01746654
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo was administered to both nares once in part A, multiple times in Part B and Part C, Once in part D
Study: NCT01658995
Drug: Doxycycline
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxycycline 100 mg oral capsules twice daily for 10 days. After 10 days, an additional Secondary treatment may be requested.
Study: NCT01658995
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, one capsule orally twice daily for 10 days. After 10 days, an additional Secondary treatment may be requested.
Study: NCT02811341
Drug: normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01165476
Drug: Treprostinil diethanolamine
Normalized name: treprostinil 1 MG (as treprostinil diethanolamine) 12 HR Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: sustained release tablets. One 1mg tablet per period. Two total doses.
Study: NCT02726386
Drug: ND0612
Approvals — FDA: no, EMA: no, PMDA: no
Description: ND0612, a solution of levodopa/carbidopa (LD/CD) delivered continuously subcutaneously (SC) via an infusion pump system
Study: NCT03885388
Drug: MTX+ACTD
Approvals — FDA: no, EMA: no, PMDA: no
Description: combination use of methotrexate and actinomycin
Study: NCT01226524
Drug: Bu Zhong Yi Qi Tang, Zhi Xue Tang, Chuan xin lian kang yan pian mod, Tian Wang Bu xin Dan
Approvals — FDA: no, EMA: no, PMDA: no
Description: A traditional Chinese Medicine (TCM) therapist will diagnose and prescribe the herbal remedies according to TCM principles from one of four formulations or any combination of the four formulation
Study: NCT04073134
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered subcutaneously using a spring-based prefilled 1.0 mL autoinjector/pen.
Study: NCT01863355
Drug: B0 group: bolus 0.6mcg/kg without background infusion
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01863355
Drug: BL group: bolus 0.4mcg/kg with background infusion rate 0.2mcg/kg/hr
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01863355
Drug: BH group: bolus 0.2mcg/kg with background infusion rate 0.4mcg/kg/hr
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03604549
Drug: Lipiodol UF
Normalized name: doxorubicin hydrochloride liposome Injection [LipoDox]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Up to 10cc of Lipiodol Ultra Fluid will be infused via intrauterine catheter
Study: NCT01731236
Drug: Antibiotics
Normalized name: Antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 3: Carnitine or Choline for 2 months, antibiotic cocktail (Ciprofloxacin, Flagyl, Vancomycin, and Neomycin) for 1 week
Study: NCT01731236
Drug: Choline and Aspirin
Normalized name: choline theophyllinate and adrenergics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 4: Choline supplement for 2 months plus aspirin 81 mg for 3 months (1 month prior to starting the study and 2 months during the study).
Study: NCT04432207
Drug: Standard of care chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy to be administered according to the prescribing information.
Study: NCT00678327
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00678327
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT00678327
Drug: prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given orally
Study: NCT05303961
Drug: SA001 1,080mg or Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cohort 4 in the Part1(Single dose): Study drug(SA001 1,080mg), Comparator(Placebo)
Study: NCT05303961
Drug: SA001 1,080mg or Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cohort 7 in the Part2(Multiple dose): Study drug(SA001 1,080mg), Comparator(Placebo)
Study: NCT03357159
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: In the first phase escalated doses of post-transplant cyclophosphamide up to a maximal dose of 50 mg/kg , the second phase will use the MTD cyclophosphamide dose identified in the first phase.
Study: NCT01822340
Drug: HM10560A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once weekly HM10560A
Study: NCT00860600
Drug: PG2
Normalized name: Fossaoprin SPG2 KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500mg/vial, iv infusion, 3 \~ 5 times/week, 2.5 \~ 3.5 hr/time
Study: NCT01493596
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: An equal volume of water mixed with juice will be administered.
Study: NCT01030094
Drug: Normal control
Normalized name: Precision, Normal Control
Approvals — FDA: no, EMA: no, PMDA: no
Description: This is an observational study. Healthy female participants will be observed in Normal control group.
Study: NCT00027417
Drug: Liothyronine sodium/triiodothyronine
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02730455
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched placebo
Study: NCT02004067
Drug: Refresh Endura
Normalized name: Refresh Endura
Approvals — FDA: no, EMA: no, PMDA: no
Description: Refresh Endura is a topical lubricant produced by Allergan, Inc.
Study: NCT04006873
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: As per description in arms
Study: NCT04326933
Drug: Tyrosine kinase Inhibitors (Imatinib & Nilotinib)
Normalized name: Tyrosine
DrugBank: Tyrosine (DB00135)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administration of tyrosine kinase inhibitors (Imatinib in a dose of 400mg/day \& Nilotinib in adose of 600mg/day)
Study: NCT02339740
Drug: Tretinoin
Normalized name: Tretinoin
DrugBank: Tretinoin (DB00755)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT00645944
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo or inactive substance (sugar pill)taken each night for all weeks of the study
Study: NCT02260258
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal Saline
Study: NCT00528333
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV administration on days 1, 8, 15, and 22 of cycle 1 and days 1 and 15 of each subsequent 28-day cycle up to a maximum of 12 cycles
Study: NCT03693833
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Placebo tablets of 10mg each
Study: NCT02875028
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03944109
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: lyophilized formulation~Route of administration: subcutaneous
Study: NCT04405739
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral placebo capsule
Study: NCT01436643
Drug: Fluoxetine
Normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluoxetine starting dose was 20 mg and given once daily for at least 7 days and a maximum of 28 days. Dosage was increased afterwards to the individual final dose given once daily, i.e. after at least 7 days and a maximum of 28 days, patients were titrated to their maximum dose of 40 Mg
Study: NCT03825744
Drug: Placebo+Standard Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: once daily
Study: NCT00940251
Drug: Mersina
Normalized name: Yersinia enterocolitica
Approvals — FDA: no, EMA: no, PMDA: no
Description: capsule, 3g/day, 3 months
Study: NCT02176057
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00198536
Drug: Vehicle
Normalized name: Drug vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03427801
Drug: Erythropoiesis-Stimulating Agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: erythropoiesis-stimulating agent: Mircera or Darbepoietin
Study: NCT03680261
Drug: chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: CT (6 cycles CT: Xelox or SOX, Q21d×3) will be applied to radical resected advanced gastric cancer patients with lymph node metastasis and lymphovascular Invasion.
Study: NCT00562120
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single oral dose of Placebo is dosed during the study in order to ascertain the effect of placebo on measures and in order to maintain the blind of the other drugs.
Study: NCT04975724
Drug: Liposom Forte
Normalized name: Erythroped Forte
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liposom Forte 28mg/2ml solution for injection contains a mixture of purified hypothalamic phospholipids (PLs) from swine brains. The key components of the phospholipid mixture are phosphatidylcholine (PC), phosphatidylethanolamine (PE) and phosphatidylserine (PS).
Study: NCT00923598
Drug: 0.1% and 0.4% perineural ropivicaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be randomized to one of two groups: Ropivicaine 0.1% infusion on the right leg and Ropivicaine 0.4% infusion on the left leg, or Ropivicaine 0.4% infusion on the right leg and Ropiviciane 0.1% infusion on the left leg for treatment of postoperative pain following bilateral TKA. Both groups will receive the same total dose of medication and will have the infusion for the two days following surgery.
Study: NCT03799822
Drug: Vitamin K Antagonist - Drug
Normalized name: Vitamin K antagonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: treatment with a vitamin K antagonist
Study: NCT01129960
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets will be used.
Study: NCT01337596
Drug: LY2951742
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered subcutaneously
Study: NCT01337596
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered subcutaneously
Study: NCT01652586
Drug: dexmedetomidine-remifentanil
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01652586
Drug: midazolam-remifentanil
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01362296
Drug: GSK1120212
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral once daily
Study: NCT02452528
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00568711
Drug: doxycycline
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: a 5-day course of 100 mg bid doses of doxycycline
Study: NCT03168906
Drug: NEOD001
Approvals — FDA: no, EMA: no, PMDA: no
Description: NEOD001 is a monoclonal antibody directed at soluble and insoluble light chain aggregates
Study: NCT03168906
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline bag
Study: NCT01008007
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment consisting in: intramuscular injection of one bulb of Dipyrone (600 mg) every 8 hours if fever is greater or equal to 38 ºC; intramuscular injection of one bulb of dimenhydrinate (50 mg) every 8 hours if vomiting; oral rehydration solution (8 ounce) after each diarrhea.
Study: NCT04108962
Drug: Fasenra, 30 Mg/mL Subcutaneous Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-IL5 receptor alpha monoclonal antibody
Study: NCT01465568
Drug: bisphosphonates
Normalized name: Bisphosphonates
Approvals — FDA: no, EMA: no, PMDA: no
Description: continue present bisphosphonate treatment
Study: NCT00349401
Drug: ketorolac
Normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00549341
Drug: Mentor Purified Toxin, Botulinum Toxn Type A, Purified Neurotoxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100U vials, doses ranged from 50U-200U, single injection.
Study: NCT01696565
Drug: PG2
Normalized name: Fossaoprin SPG2 KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injectable
Study: NCT02335372
Drug: Acetic Acid
Normalized name: Acetic acid
DrugBank: Acetic acid (DB03166)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3-6% acetic acid applied to cervix after wide-field while light imaging during colposcopy.
Study: NCT00697801
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo delivered by nebulization twice daily for 6 weeks
Study: NCT02381249
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose 0.9% saline (1mL), subcutaneously to the lower abdomen
Study: NCT02485158
Drug: Placebo beverage
Approvals — FDA: no, EMA: no, PMDA: no
Description: This is a within-subjects, double-blind, placebo controlled design. We administered a drink containing cranberry juice plus 1% alcohol added as a taste mask.
Study: NCT01347008
Drug: Placebo (Sugar pill)
Normalized name: placebo Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo pills similar to sildenafil citrate pills, b.i.d for 8 weeks
Study: NCT00030407
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: On day -7 of the first cycle, patients will start, Celecoxib 400 mg po bid daily, each dose to give with meals